Drug
Capecitabine clinical trials
Also written Xeloda, Ro 09-1978/000 and NSC-712807.
- studies test it
- 1,069
- open now
- 152
- in phase 3
- 178
- first study started
- 1997
Keep track of what changes. Save the Capecitabine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
1,064 studies that test it; most in 2004 (77); 1 more planned to start later
| Year | Studies |
|---|---|
| 1997 | 1 |
| 1998 | 3 |
| 1999 | 6 |
| 2000 | 9 |
| 2001 | 15 |
| 2002 | 40 |
| 2003 | 52 |
| 2004 | 77 |
| 2005 | 54 |
| 2006 | 67 |
| 2007 | 53 |
| 2008 | 49 |
| 2009 | 58 |
| 2010 | 46 |
| 2011 | 40 |
| 2012 | 31 |
| 2013 | 35 |
| 2014 | 27 |
| 2015 | 24 |
| 2016 | 32 |
| 2017 | 36 |
| 2018 | 39 |
| 2019 | 28 |
| 2020 | 45 |
| 2021 | 37 |
| 2022 | 33 |
| 2023 | 33 |
| 2024 | 37 |
| 2025 | 39 |
| 2026 | 18 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 265
- Phase 2
- 713
- Phase 3
- 178
- Phase 4
- 18
- No phase
- 30
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 184 · Other 885
Hoffmann-La Roche (46) · Fudan University (31) · National Cancer Institute (NCI) (28) · Sun Yat-sen University (26) · M.D. Anderson Cancer Center (21) · ImmunityBio, Inc. (17) · Alliance for Clinical Trials in Oncology (15) · Asan Medical Center (14)
Often tested with
Tested in the same studies.
Oxaliplatin (260) · Bevacizumab (121) · Docetaxel (96) · Gemcitabine (82) · Fluorouracil (77) · Cisplatin (74) · Paclitaxel (72) · Irinotecan (61)
Studies
Open first, then newest update. How each study uses Capecitabine is read from its arms, and is right about nine times in ten.
Testing it · 1,069
- Selective Internal Radiation Therapy and Capecitabine (Chemotherapy) Treatment for Liver CancerRecruitingPhase 2Center Eugene MarquisNCT05265208Written as Capecitabine
- MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPCRecruitingPhase 2Fujian Cancer HospitalNCT07331428Written as Capecitabine
- A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)RecruitingPhase 1/2National Cancer Institute (NCI)NCT05849480Written as capecitabine
- A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal AdenocarcinomaRecruitingPhase 2AstraZenecaNCT07069712Written as Capecitabine
- Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric CancerRecruitingPhase 2Jinbo YueNCT07007182Written as Capecitabine / S-1 (radiosensitizer during IMRT)
- A Single-arm, Prospective Phase Ⅱ Clinical Study of Utidelone Combined With Capecitabine in the Treatment of Active Brain Metastasis of TNBCRecruitingPhase 2Henan Cancer HospitalNCT06598046Written as Utidelone and capecitabine
- A Multicenter, Randomized, Controlled Phase III Clinical Trial on Adjuvant Intensified Therapy for Patients With Residual Disease After Neoadjuvant Treatment for Triple-negative Breast CancerNot yet recruitingPhase 3Shandong Cancer Hospital and InstituteNCT07869628Written as Capecitabine and PD-1 inhibitor
- CapTemY90 for Grade 2/3 NET Liver MetastasesRecruitingPhase 2Abramson Cancer Center at Penn MedicineNCT04339036Written as Capecitabine Oral Product
- NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal CancerRecruitingPhase 1M.D. Anderson Cancer CenterNCT04615013Written as Capecitabine
- Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast CancerRecruitingPhase 2University of Alabama at BirminghamNCT06105684Written as Capecitabine Pill
- Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable CancersRecruitingPhase 1National Cancer Institute (NCI)NCT05803382Written as Capecitabine
- Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the PancreasRecruitingPhase 2Proton Collaborative GroupNCT02598349Written as Capecitabine
- Capecitabine in Low Risk Triple Negative Breast CancerRecruitingPhase 2Fudan UniversityNCT06787339Written as Capecitabine
- Pan Tumor Rollover StudyRecruitingPhase 2Bristol-Myers SquibbNCT03899155Written as Capecitabine
- PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)RecruitingPhase 2Kristina A. FanucciNCT07222215Written as Capecitabine
- Capecitabine in ER+/HER2-negative Breast CancerRecruitingPhase 2University Health Network, TorontoNCT07631052Written as Capecitabine
- Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast CancerNot yet recruitingPhase 2Fujian Cancer HospitalNCT07766772Written as Capecitabine
- Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast CancerRecruitingPhase 2Stanford UniversityNCT04768426Written as Capecitabine
- Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast CancerRecruitingPhase 2Mayo ClinicNCT06525766Written as Capecitabine
- Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract CancerNot yet recruitingPhase 3UNICANCERNCT07745296Written as Ivosidenib + Capecitabine
See all 1,069 studies that test Capecitabine →
Given in every arm · 484 — Capecitabine is usual care beside what is tested
- Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant TherapyRecruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT06992336Written as Capecitabine
- Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II TrialRecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07847710Written as Capecitabine
- HIPEC Priming Followed by Serplulimab Plus SOX/XELOX in Locally Advanced Gastric CancerRecruitingPhase 2Shanghai Changzheng HospitalNCT07621484Written as Capecitabine
- A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric CancerRecruitingPhase 3Astellas Pharma Global Development, Inc.NCT07673887Written as Capecitabine
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ TrialRecruitingPhase 2National Cancer Institute (NCI)NCT03907475Written as Capecitabine
- A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric CancerRecruitingPhase 3Astellas Pharma Global Development, Inc.NCT06901531Written as Capecitabine
- CR-001 in Adult Participants With Locally Advanced or Metastatic Solid TumorsRecruitingPhase 1/2Crescent Biopharma, Inc.NCT07335497Written as Capecitabine
- A LM-302 Combination With Other Anti-Tumor Therapies Phase ll StudyRecruitingPhase 2LaNova Medicines Zhejiang Co., Ltd.NCT05934331Written as Capecitabine
- The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical TrialsRecruitingPhase 4PfizerNCT05203172Written as Capecitabine
- QLS31905 in Combination With CAPOX Versus Sintilimab in Combination With CAPOX as First-line Treatment in Patients With GC/GEJRecruitingPhase 3Qilu Pharmaceutical Co., Ltd.NCT07716449Written as Capecitabine
- A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric CancerRecruitingPhase 3AstraZenecaNCT06764875Written as Capecitabine
- Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2RecruitingPhase 3AstraZenecaNCT07431281Written as Capecitabine
- A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United StatesRecruitingPhase 2BeOne MedicinesNCT07554521Written as Capecitabine
- A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal CarcinomaRecruitingPhase 1/2Nanjing Leads Biolabs Co.,LtdNCT07791758Written as Capecitabine tablets
- Retlirafusp Alfa Combined With Zeprumetostat, Apatinib, and Chemotherapy as First-Line Treatment for Metastatic GC/GEJCNot yet recruitingPhase 2Fudan UniversityNCT07874425Written as Capecitabine
- ONO-4538 Phase II Rollover Study (ONO-4538-98)RecruitingPhase 2Ono Pharmaceutical Co., Ltd.NCT04566380Written as capecitabine
- Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has SpreadRecruitingPhase 1/2Boehringer IngelheimNCT06324357Written as Capecitabine
- A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaRecruitingPhase 3BeOne MedicinesNCT07043400Written as Capecitabine
- A Prospective, Single-center, Phase II Study of Neoadjuvant Serplulimab Plus XELOX and Bevacizumab in Locally Advanced Rectal CancerNot yet recruitingNot applicableTang-Du HospitalNCT07854964Written as Capecitabine
- Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone MetastasisRecruitingPhase 1/2Washington University School of MedicineNCT06374459Written as Capecitabine
Showing 20 of 484.
As the comparator · 147 — what is tested is compared with Capecitabine
- A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07060807Written as Capecitabine
- Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III TrialRecruitingPhase 3Shandong Cancer Hospital and InstituteNCT06850090Written as Capecitabine
- Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06393374Written as Capecitabine
- A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06312176Written as Capecitabine
- Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)RecruitingPhase 3Gilead SciencesNCT05633654Written as Capecitabine
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT03424005Written as Capecitabine
- Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP TrialRecruitingPhase 3ECOG-ACRIN Cancer Research GroupNCT05863195Written as Capecitabine
- A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2RecruitingPhase 3RemeGen Co., Ltd.NCT04400695Written as Capecitabine Tablets
- First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)RecruitingPhase 2Qilu Hospital of Shandong UniversityNCT06730373Written as Capecitabine
- A Prospective, Open-Label, Randomized Controlled Clinical Study Comparing Hepatic Arterial Infusion Chemotherapy (HAIC) With Capecitabine as Adjuvant Therapy After Radical Surgery for Malignant Biliary Tract TumorsRecruitingPhase 4Zhai WenlongNCT07790445Written as Capecitabine
- A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast CancerRecruitingPhase 3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07679360Written as Capecitabine tablets
- A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)RecruitingPhase 2/3Bristol-Myers SquibbNCT06926868Written as Capecitabine
- Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High StatusNot yet recruitingPhase 4Gruppo Oncologico del Nord-OvestNCT07094893Written as Capecitabine
- A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy FailureRecruitingPhase 3Sichuan Baili Pharmaceutical Co., Ltd.NCT07606599Written as Capecitabine Tablets
- A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01)RecruitingPhase 3Sichuan Baili Pharmaceutical Co., Ltd.NCT07582315Written as Capecitabine
- A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03)RecruitingPhase 3Sichuan Baili Pharmaceutical Co., Ltd.NCT07648914Written as Capecitabine
- A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid TumorRecruitingPhase 1/2Jiangsu HengRui Medicine Co., Ltd.NCT07140393Written as Trastuzumab+ Capecitabine
- Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingPhase 3Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.NCT07385703Written as Capecitabine Tablets
- Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA MutationsNot yet recruitingPhase 3Fudan UniversityNCT07628504Written as Capecitabine
- YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast CancerRecruitingPhase 3MediLink Therapeutics (Suzhou) Co., Ltd.NCT07461454Written as Capecitabine
Showing 20 of 147.
Codes
What other systems call Capecitabine · ClinicalTrials.gg INT006570
- MeSH (NLM) D000069287CapecitabineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 6804DJ8Z9UCAPECITABINEConfirmed FDA, NLM, Wikidata
- RxNorm 194000Confirmed FDA, Wikidata
- Wikidata Q420207capecitabineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1794CapecitabineOne source FDA
- DrugBank DB01101One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000069287 | Capecitabine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 6804DJ8Z9U | CAPECITABINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 194000 | — | Confirmed FDA, Wikidata |
| Wikidata | Q420207 | capecitabine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1794 | Capecitabine | One source FDA |
| DrugBank | DB01101 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.